Objective: The rising occurrence of drug-resistant pathogens accentuates the need to identify novel antibiotics. We wanted to identify new scaffolds for drug discovery by repurposing FDA-approved drugs against Acinetobacter baumannii, an emerging Gram-negative nosocomial drug-resistant pathogen.
Introduction
Drug-resistant Acinetobacter baumannii has the distinction of simultaneously being a National Institute of Allergy and Infectious Diseases (NIAID) Category C pathogen and one of the six most dangerous multidrug-resistant (MDR) microbes in the Infectious Disease Society of America (IDSA) rogues' gallery. 1 It accounts for 6% of Gram-negative infections in intensive care facilities in the USA, with mortality rates as high as 54% having been reported by the IDSA. Isolation of MDR Acinetobacter soared from 6.7% in 1993 to 29.9% by 2004, emphasizing the need for newer and better drugs. 2 'Iraqibacter' infections have gained notoriety with regard to trauma associated with soldiers in the Persian Gulf and Vietnam. In recent years, the pharmaceutical industry has reduced antimicrobial drug development programmes for a multitude of reasons, including antibiotic resistance and lower profit margins. Even newly FDA-approved drugs such as linezolid (2000) and daptomycin (2003) do not target the emerging nosocomial Gram-negative pathogens, thus exacerbating the dearth of new drugs. 3 Repurposing or repositioning of FDA-approved pharmacotherapies for off-label use is considered to be a less risky enterprise than de novo drug discovery and is a more systematic approach to identifying new classes of antibiotics and scaffolds in response to the continuous rise of MDR pathogens. Several examples of successful repurposing include buproprion (Wellbutrin), which was developed to treat depression, but has found use in smoking cessation (marketed as Zyban) and duloxetine (Cymbalta), which was developed to treat depression and is being used to treat stress urinary incontinence. 4 In this study, we screened the Microsource US Drug Library against drug-susceptible (DS) and MDR strains of A. baumannii. The purpose of this screening effort was 2-fold. First, we wanted to identify any non-antimicrobial drugs exhibiting significant activity against A. baumannii. Second, we wanted to get an overview of the biological activity of the panel of existing antimicrobials against the DS and MDR A. baumannii. We hypothesized that comparing the biological activities of different classes of antibiotics against DS and MDR A. baumannii would identify the patterns and extent of drug resistance and provide 
Materials and methods

Compounds and library
The drug library procured from Microsource, Inc. (http://www. msdiscovery.com/usdrugs.html) contained 1040 drugs that have reached clinical trial stages in the USA and have been assigned US Pharmacopeia (USP) status. The library was provided in a 96-well plate format with aliquots of 10 mM stocks of drugs in DMSO. Other antibiotics were purchased from Sigma-Aldrich (St Louis, MO, USA) and solubilized according to the manufacturer's instructions, and aliquots were stored at 2208C.
Bacterial strains and growth conditions
The A. baumannii strains were procured from the ATCC (ATCC, Manassas, VA, USA). ATCC 17978 is a DS strain isolated in 1951 from a 4-month-old infant with fatal meningitis. It exhibits susceptibility to the majority of clinically utilized antibiotics. BAA-1605 is an MDR strain isolated from the sputum of a Canadian soldier who served in Afghanistan in 2006 and exhibits resistance to ceftazidime, gentamicin, ticarcillin, piperacillin, aztreonam, cefepime, ciprofloxacin, imipenem and meropenem, but is susceptible to amikacin and tobramycin. Mueller-Hinton broth II (MHB II) (Becton Dickinson) was used to propagate the bacteria.
The library was initially screened at a single concentration point ( 16 mg/L) according to CLSI guidelines (CLSI, Wayne, PA, USA) to identify 'hit' compounds against both strains.
5 The 96-well plates were incubated at 378C for 18-24 h and the antimicrobial activity was determined by visual inspection. The MIC of the active compounds was determined and was defined as the lowest concentration of the compound that inhibited visible growth after 24 h. We defined significant antimicrobial activity as MIC ≤8 mg/L against either strain. The experiments were conducted in duplicate and the results are shown in Table 1 .
Results
Only a small percentage of the compounds tested (20/1040 or 1.92%) exhibited significant antimicrobial activity (MIC ≤8 mg/L), despite the high prevalence of known antibiotics. Those compounds that did exhibit activity fell into classical antimicrobial drug categories. In comparison with polymyxin B, 13 drugs exhibited comparable or better activity against ATCC 17978 whereas only 1 drug exhibited comparable activity against BAA-1605. This extremely low number of compounds significantly active against BAA-1605 is a testament to the ability of MDR A. baumannii to resist antimicrobials.
Among the most potent class of compounds identified against ATCC 17978 were the fluoroquinolones, especially gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin and sarafloxacin, with MICs ,0.04 mg/L, even though BAA-1605 was resistant to all of the fluoroquinolones tested. However, not all fluoroquinolones exhibited equally potent activity, as evidenced by an increasing range of MIC from enrofloxacin to lomefloxacin (Table 1) .
On the other hand, doxycycline HCl exhibited significantly potent activity (MIC 0.37 mg/L) while kanamycin A sulphate and minocycline HCl exhibited moderate activity against 
Discussion
A. baumannii's ability to survive in a multitude of natural environments, combined with its ability to acquire an impressive range of antibiotic resistance determinants, renders it a successful nosocomial pathogen. Recent comprehensive genomic studies on A. baumannii have identified multiple alien islands on its genome acquired through horizontal gene transfer, a number of which have been extensively linked to drug resistance. 6 Our screening efforts have confirmed there are very limited options to combat A. baumannii when considering existing approved antibiotics.
Our systematic efforts for repurposing drugs for treating A. baumannii have highlighted several important observations. First, only 20 drugs exhibited significant activity against ATCC 17978, a 1.92% hit rate. This extremely low hit rate supports the idea that even the DS strain of A. baumannii is naturally resistant to many of the old and new classes of approved antibacterials.
It is known that tetracycline-resistant bacteria demonstrate increased susceptibility to semi-synthetic tetracyclines such as minocycline and doxycycline. Indeed, minocycline has been shown to be effective against A. baumannii strains resistant to doxycycline or tetracycline and imipenem. 7 Our study showed a similar trend, with doxycycline exhibiting a significant MIC against BAA-1605 (Table 1) , which suggests that semi-synthetic tetracyclines could potentially be used for the MDR strains. This, however, was not true for minocycline HCl; although its activity against ATCC 17978 was significant, it lost potency against BAA-1605 (Table 1 ). The loss in potency of the tetracycline class of compounds against BAA-1605 is probably mediated by a combination of efflux pumps and ribosomal protection protein(s).
Our screening also identified the fluoroquinolone class as exhibiting extremely potent activity against ATCC 17978 (some MICs ,0.03 mg/L) ( Table 1 ). This gain, however, was offset by the complete absence of fluoroquinolone activity against BAA-1605, epitomizing class resistance. Resistance to fluoroquinolones in A. baumannii is mediated by mutations in quinolone resistance determining regions in the gyrA and parC genes, which have been demonstrated for BAA-1605. 8 Since MDR A. baumannii is being encountered with increasing frequency in the clinic, the identification of fluoroquinolones as possessing potent activity against DS strains but not against MDR strains does not bode well for the use of fluoroquinolones as a long-term treatment strategy.
We also identified the antimicrobial peptide family (specifically cyclic peptides) as possessing equipotent activity against ATCC 17978 and BAA-1605 (Table 1) . Tyrothricin is a complex mixture of polypeptide antimicrobials consisting of gramicidins ( 15%) and tyrocidins ( 85%). The precise molecular composition of this complex mixture remains unclear, as mass spectrometry studies indicate a mixture of over 30 compounds. 9 It is important to highlight that tyrothricin is primarily used as an antibiotic against Gram-positive bacteria such as Staphylococcus aureus. Our study, however, suggests that this mixture of peptide antibiotics could also be used effectively against A. baumannii. Recently, antimicrobial peptides such as rBPI 2 and cecropin P1 have demonstrated potent activity against polymyxin B-resistant A. baumannii. 10 Currently, tyrothricin is available for topical application only, since systemic intake can lead to severe side effects. Even though tyrothricin can be repurposed for wound infections caused by A. baumannii, developing peptide therapies for systemic infections is challenged by cost, manufacturing, delivery and toxicity issues. The synergistic activity of tyrothricin with other clinically utilized antibiotics needs to be further studied.
Rapidly developing antibiotic resistance is hindering efforts to discover novel and effective antibiotics for treating pan-resistant bacteria. Our studies indicate that an effective antibiotic for MDR A. baumannii could emerge from semi-synthetic tetracyclines and antimicrobial peptides. Our screening effort also provides insights into the chemical biology of antibiotic resistance, which may be helpful in selecting scaffolds for the next generation of antibiotics. For example, we found that while levofloxacin and related molecules are highly effective against ATCC 17978, the MDR BAA-1605 strain shows resistance to the entire class. To provide a long-term solution to the problem of drug resistance, it will be important to develop systems-level models of antibiotic resistance pathways. Systems biology approaches are likely to identify targets that can delay the development of resistance. To the best of our knowledge, this study presents the first systematic effort for preliminary repurposing approved drugs to tackle the growing menace of MDR A. baumannii.
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